Loading organizations...
§ Private Profile · Ottawa, ON, Canada
Synthetic biology platforms using modified exosomes for disease treatment and prevention, particularly cancer and infectious diseases.
Based in Ottawa, Ontario, Esphera SynBio is a biotechnology company that develops synthetic biology platforms utilizing modified exosomes for the treatment and prevention of cancer and infectious diseases. The enterprise engineers cells either in vitro or in vivo to produce targeted exosomes equipped with specific protein or RNA payloads, enabling the creation of patient-specific therapeutics such as personalized oncology vaccines. Operating as an early-stage venture without current commercial revenue, the firm has secured approximately $3 million in seed funding to advance its clinical pipeline and prepare for a planned Series A round. This financial backing includes capital from institutional investors GKCC LLC and FACIT, which supported the company as it filed five patents for its biological delivery mechanisms. Esphera SynBio was founded in 2022 by Brian Lichty, Carolina Ilkow, and John Bell.
Esphera SynBio has raised $2.0M across 1 funding round.
Esphera SynBio has raised $2.0M in total across 1 funding round.
Esphera SynBio has raised $2.0M across 1 funding round. Most recently, it raised $2.0M Seed in January 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 8, 2025 | $2M Seed | — | — | Announced |
Esphera SynBio has raised $2.0M in total across 1 funding round.